Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-10-28 Sale | 2024-10-30 4:35 pm | Monte Rosa Therapeutics Inc. | GLUE | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner | 157,895 | $9.4432 | $1,491,041 | 7,137,269 (Indirect Direct) | View |
| 2024-09-20 Sale | 2024-09-24 4:40 pm | Monte Rosa Therapeutics Inc. | GLUE | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner | 1,132,566 | $6.5296 | $7,395,203 | 7,197,274 (Indirect Direct) | View |
| 2024-09-11 Sale | 2024-09-13 6:44 pm | Monte Rosa Therapeutics Inc. | GLUE | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner | 567,213 | $6.0027 | $3,404,791 | 8,329,840 (Indirect Direct) | View |
| 2024-07-05 Sale | 2024-07-09 4:15 pm | Monte Rosa Therapeutics Inc. | GLUE | Dunn Edmund Principal Accounting Officer | 1,610 | $3.8301 | $6,166 | 13,944 (Direct) | View |
| 2024-06-03 Sale | 2024-06-05 4:10 pm | Monte Rosa Therapeutics Inc. | GLUE | Dunn Edmund Principal Accounting Officer | 1,207 | $4.0396 | $4,876 | 15,554 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-10-28 Other | 2024-10-30 4:35 pm | N/A N/A | Monte Rosa Therapeutics Inc. | GLUE | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner | 1,435,402 | $0 | 7,137,269 (Direct) | View |
| 2024-09-13 Option Award | 2024-09-13 4:30 pm | N/A 2032-10-04 | Monte Rosa Therapeutics Inc. | GLUE | Janku Filip Chief Medical Officer | 30,000 | $0 | 30,000 (Direct) | View |
| 2024-06-12 Option Award | 2024-06-13 8:12 pm | N/A 2034-06-12 | Monte Rosa Therapeutics Inc. | GLUE | Behbahani Ali Director 10% Owner | 22,100 | $0 | 22,100 (Direct) | View |
| 2024-06-12 Option Award | 2024-06-13 4:30 pm | N/A 2034-06-12 | Monte Rosa Therapeutics Inc. | GLUE | SCHIFF ANDREW N Director | 22,100 | $0 | 22,100 (Direct) | View |
| 2024-06-12 Option Award | 2024-06-13 4:30 pm | N/A 2034-06-12 | Monte Rosa Therapeutics Inc. | GLUE | Siu Christine Director | 22,100 | $0 | 22,100 (Direct) | View |
| 2024-06-12 Option Award | 2024-06-13 4:30 pm | N/A 2034-06-12 | Monte Rosa Therapeutics Inc. | GLUE | Skvarka Jan Director | 22,100 | $0 | 22,100 (Direct) | View |
| 2024-06-12 Option Award | 2024-06-13 4:30 pm | N/A 2034-06-12 | Monte Rosa Therapeutics Inc. | GLUE | Manning Anthony M. Director | 22,100 | $0 | 22,100 (Direct) | View |
| 2024-06-12 Option Award | 2024-06-13 4:30 pm | N/A 2034-06-12 | Monte Rosa Therapeutics Inc. | GLUE | Blackwell Kimberly Director | 22,100 | $0 | 22,100 (Direct) | View |
| 2024-06-03 Option Award | 2024-06-05 4:10 pm | N/A 2034-06-03 | Monte Rosa Therapeutics Inc. | GLUE | Nickson Philip Chief Business & Legal Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-03 Option Award | 2024-06-05 4:10 pm | N/A 2034-06-03 | Monte Rosa Therapeutics Inc. | GLUE | Townson Sharon Chief Scientific Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-03 Option Award | 2024-06-05 4:10 pm | N/A 2034-06-03 | Monte Rosa Therapeutics Inc. | GLUE | Champoux Jennifer Chief Operating Officer | 40,000 | $0 | 40,000 (Direct) | View |
Ownership | 2024-06-05 4:05 pm | N/A 2031-04-12 | Monte Rosa Therapeutics Inc. | GLUE | Champoux Jennifer Chief Operating Officer | 0 | $0 | 305,120 (Direct) | View |
Ownership | 2024-06-05 4:05 pm | N/A 2030-08-14 | Monte Rosa Therapeutics Inc. | GLUE | Townson Sharon Chief Scientific Officer | 0 | $0 | 517,851 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:15 pm | N/A 2034-01-01 | Monte Rosa Therapeutics Inc. | GLUE | Warmuth Markus President & CEO | 346,000 | $0 | 346,000 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:15 pm | N/A 2034-01-01 | Monte Rosa Therapeutics Inc. | GLUE | Wallace Owen B. Chief Scientific Officer | 119,000 | $0 | 124,266 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:15 pm | N/A 2034-01-01 | Monte Rosa Therapeutics Inc. | GLUE | Jones Jullian G Chief Business Officer | 79,000 | $0 | 79,000 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:15 pm | N/A 2034-01-01 | Monte Rosa Therapeutics Inc. | GLUE | Janku Filip Chief Medical Officer | 121,000 | $0 | 126,252 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:15 pm | N/A 2034-01-01 | Monte Rosa Therapeutics Inc. | GLUE | Nickson Philip General Counsel | 109,000 | $0 | 109,000 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:15 pm | N/A 2034-01-01 | Monte Rosa Therapeutics Inc. | GLUE | Dunn Edmund Principal Accounting Officer | 60,900 | $0 | 60,900 (Direct) | View |
Ownership | 2023-08-18 4:00 pm | N/A N/A | Monte Rosa Therapeutics Inc. | GLUE | Dunn Edmund Principal Accounting Officer | 0 | $0 | 92,876 (Direct) | View |
| 2023-07-25 Option Award | 2023-07-26 4:10 pm | N/A 2033-07-24 | Monte Rosa Therapeutics Inc. | GLUE | Manning Anthony M. Director | 41,000 | $0 | 41,000 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-15 4:42 pm | N/A 2033-06-13 | Monte Rosa Therapeutics Inc. | GLUE | Behbahani Ali Director 10% Owner | 20,500 | $0 | 20,500 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-15 4:29 pm | N/A 2033-06-13 | Monte Rosa Therapeutics Inc. | GLUE | Skvarka Jan Director | 20,500 | $0 | 20,500 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-15 4:28 pm | N/A 2033-06-13 | Monte Rosa Therapeutics Inc. | GLUE | Siu Christine Director | 20,500 | $0 | 20,500 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-15 4:28 pm | N/A 2033-06-13 | Monte Rosa Therapeutics Inc. | GLUE | SCHIFF ANDREW N Director | 20,500 | $0 | 20,500 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-15 4:27 pm | N/A 2033-06-13 | Monte Rosa Therapeutics Inc. | GLUE | Mayweg Alexander Director | 20,500 | $0 | 20,500 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-15 4:26 pm | N/A 2033-06-13 | Monte Rosa Therapeutics Inc. | GLUE | Blackwell Kimberly Director | 20,500 | $0 | 20,500 (Direct) | View |
| 2023-03-30 Option Award | 2023-03-31 4:15 pm | N/A 2033-03-29 | Monte Rosa Therapeutics Inc. | GLUE | Skvarka Jan Director | 41,000 | $0 | 41,000 (Direct) | View |
| 2023-01-03 Option Award | 2023-01-04 4:31 pm | N/A 2033-01-02 | Monte Rosa Therapeutics Inc. | GLUE | Wallace Owen B. Chief Scientific Officer | 135,000 | $0 | 135,000 (Direct) | View |
| 2023-01-03 Option Award | 2023-01-04 4:31 pm | N/A 2033-01-02 | Monte Rosa Therapeutics Inc. | GLUE | Warmuth Markus President & CEO | 472,000 | $0 | 472,000 (Direct) | View |
| 2023-01-03 Option Award | 2023-01-04 4:31 pm | N/A 2033-01-02 | Monte Rosa Therapeutics Inc. | GLUE | Nickson Philip General Counsel | 123,650 | $0 | 123,650 (Direct) | View |
| 2023-01-03 Option Award | 2023-01-04 4:31 pm | N/A 2033-01-02 | Monte Rosa Therapeutics Inc. | GLUE | Townson Sharon Chief Technology Officer | 78,550 | $0 | 78,550 (Direct) | View |
| 2023-01-03 Option Award | 2023-01-04 4:30 pm | N/A 2033-01-02 | Monte Rosa Therapeutics Inc. | GLUE | Jones Jullian G Chief Business Officer | 77,450 | $0 | 77,450 (Direct) | View |
| 2023-01-03 Option Award | 2023-01-04 4:30 pm | N/A 2033-01-02 | Monte Rosa Therapeutics Inc. | GLUE | Castle John C. Chief Data Scientist | 78,500 | $0 | 78,500 (Direct) | View |